Merle Diamond
Overview
Explore the profile of Merle Diamond including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
380
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Blumenfeld A, Mechtler L, Cook L, Rhyne C, Jenkins B, Hughes O, et al.
Neurology
. 2025 Feb;
102(7_supplement_1):3371.
PMID: 39977883
Objective: To collect real-world data to evaluate the effectiveness, safety, and tolerability of adding atogepant to onabotulinumtoxinA as combination preventive treatment for chronic migraine (CM). Background: Combination use of atogepant...
2.
Blumenfeld A, Mechtler L, Cook L, Rhyne C, Jenkins B, Hughes O, et al.
Pain Ther
. 2024 Dec;
14(1):441-444.
PMID: 39718742
No abstract available.
3.
Blumenfeld A, Mechtler L, Cook L, Rhyne C, Jenkins B, Hughes O, et al.
Pain Ther
. 2024 Sep;
13(6):1571-1587.
PMID: 39287781
Introduction: Combination use of atogepant and onabotulinumtoxinA has the potential to be more effective than either alone for the preventive treatment of chronic migraine (CM) due to their complementary mechanisms...
4.
Klein B, Miceli R, Severt L, McAllister P, Mechtler L, McVige J, et al.
Cephalalgia
. 2023 Jan;
43(1):3331024221128250.
PMID: 36620892
Background: Atogepant is a United States Food and Drug Administration-approved oral calcitonin gene-related peptide receptor antagonist for the preventive treatment of episodic migraine. The study objective was to evaluate the...
5.
Silberstein S, Diamond M, Hindiyeh N, Biondi D, Cady R, Hirman J, et al.
J Headache Pain
. 2020 Oct;
21(1):120.
PMID: 33023473
Background: PROMISE-2 was a phase 3, randomized, double-blind, placebo-controlled study that evaluated the efficacy and safety of repeat intravenous (IV) doses of the calcitonin gene-related peptide-targeted monoclonal antibody eptinezumab (ALD403)...
6.
Feoktistov A, Diamond M
Otolaryngol Clin North Am
. 2014 Apr;
47(2):175-85.
PMID: 24680487
Primary headaches are the most common headache disorders. The most common forms are tension-type headaches, migraine, and cluster headache. Knowing the clinical presentation coupled with taking a thorough history taking...
7.
Friedman B, Serrano D, Reed M, Diamond M, Lipton R
Headache
. 2008 Dec;
49(1):21-30.
PMID: 19040677
Background: Although headache is a common emergency department (ED) chief complaint, the role of the ED in the management of primary headache disorders has rarely been assessed from a population...
8.
Freitag F, Diamond M, Diamond S, Janssen I, Rodgers A, Skobieranda F
Headache
. 2008 Jun;
48(6):921-30.
PMID: 18572432
Objective: To evaluate the efficacy and tolerability of coadministration of rizatriptan and acetaminophen in the acute treatment of migraine. Background: Rizatriptan is a selective 5-HT1B/1D agonist approved for the acute...
9.
Brown J, Neumann P, Papadopoulos G, Ruoff G, Diamond M, Menzin J
Value Health
. 2008 Apr;
11(2):315-21.
PMID: 18380644
Objectives: Assess the relationship between migraine frequency and health utility. Methods: Patients aged >/=18 years diagnosed with episodic migraine were enrolled at three US sites representing varied models of health-care...
10.
Freitag F, Diamond S, Diamond M, Urban G
Headache
. 2007 Nov;
48(2):201-9.
PMID: 18042229
Introduction: Chronic migraine is a recent diagnostic term that has undergone evolution from its original description. Clinically it has been believed that medication overuse contributed to its development and would...